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Abstract: Lung cancer—predominantly non-small cell lung cancer
(NSCLC)—is the leading cause of death from cancer in most
industrialized countries. Patients with early-stage NSCLC are at
substantial risk for recurrence and death even after potentially
curative surgery. Multiple large randomized trials have demon-
strated that adjuvant chemotherapy using modern cisplatin-based
regimens can significantly improve 5-year survival in carefully
selected patients with NSCLC.
The current staging system is inadequate for predicting the
outcome of treatment and the prognosis in an individual patient.
Molecular markers may provide additional information about the
likelihood of relapse beyond that obtained from pathologic staging.
They may also have value in determining which patients will benefit
from adjuvant platinum-based chemotherapy.
This is a review focused on approaches and specific markers
under study, including gene expression profiles, DNA repair path-
ways, class III -tubulin expression, abnormalities in the k-ras
oncogene and p53 tumor suppressor gene, and DNA methylation
markers. Additional studies will be required to determine whether
these markers are useful in selecting patients for adjuvant platinum-
based chemotherapy.
Key Words: Non-small cell lung cancer, Early stages, Platinum-
based adjuvant chemotherapy, Molecular prognostic and predictive
markers.
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Lung cancer is the most common cause of death from cancerworldwide, and non-small cell lung cancer (NSCLC) ac-
counts for almost 80% of such deaths.1 Patients with early-
stage NSCLC are at substantial risk for recurrence even after
potentially curative surgical resection and 5-year survival
ranges from only 30 to 60%. As many as 40% of patients with
stage I, 66% of stage II and 75% of stage IIIA patients will
develop recurrence and die as a result of their disease within
5 years of resection.2–4
Several recent trials using cisplatin-based doublets have
demonstrated that adjuvant chemotherapy improves 5-year over-
all survival (OS) by 8 to 15% in carefully selected patients with
completely resected stages II and IIIA NSCLC.5–7 Its role in
stage IB disease is less established, and it is not currently
recommended for routine use. Neither the Lung Adjuvant Cis-
platin Evaluation meta-analysis8 nor any of the recently pub-
lished large randomized clinical trials (NCIC-CTG JBR.10,7
ANITA,6 and International Adjuvant Lung Cancer Trial
(IALT)5) have shown a significant OS benefit for cisplatin
therapy in stage IB subgroup. Nevertheless, the Cancer and
Leukemia Group B (CALGB) 9633 study9,10 has found a non-
significant survival benefit for carboplatin-based therapy in stage
IB patients (harzard ratio [HR], 0.80; 90% two-sided confidence
interval [CI], 0.60–1.07; p  0.10) and a significant benefit in
terms of relapse-free survival (RFS) (HR, 0.74; 90% two-sided
CI, 0.57–0.96; p  0.027). Moreover, the trial reported signif-
icant OS and RFS advantages in an unplanned subset analysis of
patients with tumors 4 cm (HR, 0.66; 90% CI, 0.045–0.97,
and HR 0.62; 90% CI, 0.44–0.89, respectively). To date, very
few patients with stage IA NSCLC have been enrolled onto
randomized clinical trials, and adjuvant chemotherapy is not
recommended in these cases.
Although the current standard of treatment for patients
with stage I NSCLC is surgical resection, nearly 30 to 35% of
them will relapse after initial surgery and thus have a poor
prognosis, indicating that a subgroup of these patients might
benefit from adjuvant chemotherapy.11 Similarly, as a popu-
lation, patients with stage II or stage IIIA NSCLC receive
adjuvant chemotherapy, but some may receive potentially
toxic treatment unnecessarily. Thus, we can consider NSCLC
as a heterogeneous disease. Even in patients with similar
clinical and pathologic features, the outcome varies: some are
cured, whereas in others, the cancer recurs.
Prognostic markers are patient or tumors factors that,
independent of treatment, predict patient survival outcome.
Predictive markers are factors that may influence and predict
the outcome of treatment in terms of either response or
survival benefit.
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Although other clinical and pathologic markers have
prognostic significance,12–15 the clinic-pathologic staging sys-
tem has been the standard for determining NSCLC progno-
sis.13 But this classification scheme is probably an imprecise
predictor of the prognosis of an individual patient. Thus, main
investigational studies nowadays are focused in identifying
molecular markers of recurrence, beyond pathologic stage,
after surgical treatment and factors that can predict a benefit
from platinum adjuvant chemotherapy in poor prognosis
subgroups, to individualize treatments. This ability to identify
subgroups of patients more accurately may improve health
outcomes across the spectrum of disease. The study of mo-
lecular factors that influence drug responsiveness is also a
potentially promising approach to decrease treatment toxicity
and costs by avoiding the administration of ineffective ther-
apy to patients destined not to benefit.
Many molecular markers that predict patient survival
independent of the tumor-node-metastasis staging system
have been reported.14,16–19 These include oncogenes (K-ras,
BclII, Her2/neu, EGFR), tumor suppressor genes (p53, RB,
p16, p27), cell cycle modulators (cyclins), molecules related
to tumor invasion and metastasis (CD 44, cathepsin B, matrix
metalloproteinase), telomerase, molecules involved in tumor
angiogenesis (vascular endothelial growth factor, vascular
endothelial growth factor receptor), and cyclo-oxygenase 2.
GENE EXPRESSION PROFILES
Gene expression profiling may identify patient groups
with significantly different prognosis. They may also have
value in determining, more selectively than stage, which
patients will benefit from adjuvant chemotherapy. A number
of prognostic gene expression signatures have been reported
to predict survival in NSCLC.
Gene-expression profiling by means of microarrays20,21
and reverse-transcriptase polymerase chain reaction (RT-
PCR)16 is useful for classifying tumors and formulating a
prognosis for patients with various types of cancer, including
lung cancer. The use of microarrays in clinical practice is
limited, however, by the need for complicated methods, the
large number of genes used in genes profiling, the need for
fresh-frozen tissue and the lack of both reproducibility and
independent validation of the results.22 The genes selected for
profiling in studies of lung cancer have varied considerably
and only a few genes have been consistently included.23,24
Moreover, gene-expression profiles can vary according to the
microarray platform and the analytic strategy used.
The RT-PCR method can be applied to paraffin-em-
bedded pathologic specimens and is more useful in clinical
practice. It allows for accurate and reproducible quantifica-
tion of results for RNA obtained from histologic specimens.
However, RT-PCR can be used to analyze only a small
number of genes.22
The potential value of gene expression profiling in
NSCLC was illustrated by a Duke University study.25 Au-
thors identified a gene-expression profile—the lung metagene
model—that predicted the risk of recurrence in a cohort of 89
patients with early-stage NSCLC enrolled through the Duke
Lung Cancer Prognostic Laboratory. Pathologic stages in the
study cohort were as follow: 39 patients (44%) had stage IA,
30 (34%) stage IB, four (5%) stage IIA, 10 (11%) stage IIB,
and six (7%) stage IIIA. This genetic strategy was then
validated in two separate cohorts from multicenter coopera-
tive group trials: 25 patients from the American College of
Surgeons Oncology Group Z0030 study and 84 from the
prospective CALGB 9761 trial. Neither adjuvant chemother-
apy nor radiotherapy was allowed in any patient.
The lung metagene model represents the dominant aver-
age pattern of expression of the gene cluster across the tumor
samples. The confirmation that it represents the biology of the
tumor was provided by the finding that the metagenes with the
greatest discriminatory capability in the model included genes
that have previously been shown to have clinical relevance in
NSCLC. In some instances, a metagene represented a single
molecular process such as angiogenesis (metagene 19), which is
a proven target for therapy in NSCLC. Other key metagenes,
such as metagene 41, represented a combination of biological
processes—for example, the BRAF, phosphatidylinositol 3 qui-
nase, TP 53, and MYC signaling pathways.
The lung metagene model for the prediction of recur-
rence was superior to a predictive model generated with the
same methods but that included clinical data alone (including
age, sex, tumor diameter, stage of disease, histologic subtype,
and smoking history). In the Duke cohort, the lung metagene
model predicted disease recurrence with an overall accuracy
of 93%. The model built with clinical data had an accuracy of
only 64%. Inclusion of the clinical data with the genomic data
did not further improve the accuracy of the prediction of
recurrence over that of the genomic data alone. This model
was consistently accurate across all the early stages of
NSCLC and between the major histologic subtypes, not only
in the estimated risk of recurrence but also in the results of the
Kaplan-Meier survival analysis for each stage or subtype.
Applied to the cohorts from the American College of Sur-
geons Oncology Group Z0030 trial and the CALGB 9761
trial, this genomic strategy had an overall predictive accuracy
of 72 and 79%, respectively.
This gene expression profile also was applied to 68
patients with stage IA disease, who are not usually candidates
for adjuvant chemotherapy. Kaplan-Meier survival curves
were generated for the group as a whole and for the sub-
groups predicted to be at high or low risk for recurrence by
the lung metagene model. Although the survival rate for the
group was approximately 70% at 4 years, the survival rate for
those predicted to be at low risk was 90% and less than 10%
for those predicted to be at high risk, thus identifying the
subgroup of patients with stage IA NSCLC at high risk of
recurrence, who might benefit from adjuvant chemotherapy
(Figure 1).
In another important study from Taiwan University,26
authors examined the expression of multiple genes associated
with invasive activity in frozen specimens of lung-cancer
tissue from 125 randomly selected patients who underwent
surgical resection of NSCLC and not received adjuvant che-
motherapy, to identify a gene signature that is correlated with
clinical outcome.
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Sixteen genes were initially identified by analyzing
microarray data and then confirmed by RT-PCR. From these,
the authors further identified five genes that were significantly
associated with survival. The levels of expression of these
five genes were used to construct a decision tree to classify
patients as having a high-risk gene signature or a low-risk
gene signature. The five selected genes were: dual-specificity
phosphatase 6 (DUSP6), monocyte-to-macrophage differen-
tiation-associated protein (MMD), signal transducer and ac-
tivator of transcription 1 (STAT1), v-erb b2 avian erythro-
blastic leukemia viral oncogene homolog 3 (ERBB3), and
lymphocyte-specific protein tyrosine kinase (LCK).
The authors identified 59 patients with high-risk gene
signatures and 42 with low-risk gene signatures, according to
gene expression as measured with RT-PCR and decision-tree
analysis. The five-gene signature was strongly associated
with OS (sensitivity 98%; specificity 93%; positive predictive
value 95%; negative predictive value 98%; and overall accu-
racy 96%). The presence of a high-risk five-gene signature in
the NSCLC tumors was associated with an increased risk of
recurrence and decreased OS. With a median follow-up of 20
months, the patients with a high-risk gene signature had a
shorter median OS than the patients with a low-risk gene
signature (20 months versus 40 months, p  0.001). The
high-risk gene signature was associated with a median RFS of
13 months, whereas the low-risk gene signature was associ-
ated with a median RFS of 29 months (p 0.002) (Figure 2).
According to multivariate regression analysis, the high-
risk five-gene signature, tumor stage III and older age were
significantly associated with death from any cause among the
101 patients, and the high-risk five-gene signature and tumor
stage III were significantly associated with recurrence of
cancer as well (HR for the high-risk signature versus the
low-risk signature, 1.92; 95% CI, 1.06–3.46; p  0.03).
In a subgroup analysis of 59 patients with stage I or II
disease, those with a high-risk gene signature had a shorter
OS and a shorter RFS than those with a low-risk gene
signature (Figure 2).
These results were validated in an independent cohort
of 60 patients with NSCLC and with the use of a set of
published microarray data from 86 patients from a Western
population with NSCLC.
The identification of five genes that are closely associated
with the outcomes in patients with NSCLC has clinical impli-
cations. Patients who have tumors with a high-risk gene signa-
ture could benefit from a cisplatin-based adjuvant chemother-
apy, whereas those with a low-risk gene signature could be
spared what may be unnecessary treatment. Prospective, large
scale, multicenter studies are necessary to test this idea.
These five genes that can predict the clinical outcome in
patients with NSCLC may also reveal targets for the devel-
opment of therapy for lung cancer. STAT1 causes arrested
growth and apoptosis in many types of cancer cells by
FIGURE 1. Kaplan-Meier survival estimates for a group of
patients with stage IA disease from the Duke, ACOSOG, and
CALGB cohorts and the subgroups predicted to have either
a high probability (0.5) or a low probability (0.5) of re-
currence by the application of the Lung Metagene Model.
FIGURE 2. Kaplan-Meier esti-
mates of overall survival and re-
lapse-free survival for the 101 pa-
tients with NSCLC (Panel A and
Panel B, respectively) and for the
59 patients with stage I or stage II
disease (Panel C and Panel D, re-
spectively), according to the Five-
Gene Signature.
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inducing the expression of p21WAF1 and caspase.27,28 MMD
is preferentially expressed in mature macrophages.29 Some
studies have shown that macrophage activation promotes
cancer metastasis,30 although the function of the MMD pro-
tein is unknown. DUSP6 inactivates extracellular signal-
regulated kinase 2 (also known as mitogen-activated protein
kinase 1), resulting in tumor suppression and apoptosis.31
ERBB3, a member of the epidermal growth factor receptor
family of tyrosine kinases, can shorten cell survival.32 LCK,
a member of the Src family of protein tyrosine kinases, is
expressed mainly in T cells and is one of the first signaling
molecules downstream of the T-cell receptor. It plays a key
role not only in the differentiation and activation of T cells
but also in the induction of apoptosis.33 In addition, LCK is
expressed in many cancers and regulates the mobility of
cancer cells.34,35
Skrzypski et al.36 examined the expression pattern of 29
genes selected by cDNA studies to test their clinical prog-
nostic value in early-stage squamous cell carcinoma (SCC) of
the lung. From 2000 to 2004, freshly frozen primary tumor
specimens were obtained at the time of the surgery from 66
SCC patients and gene expression of the 29 genes was
assessed by quantitative RT-PCR using low-density arrays.
Expression values were dichotomized using the median value
as the cutoff. The univariate analysis showed 10 genes with
prognosis value: PH4 (p  0.01); macrophage-colony stim-
ulating factor (CSF1), which attracts macrophages and induce
them to express EGF (p  0.002); EGFR (p  0.05);
KIAA0974 (p  0.02); ANLN (p  0.02); carbonic anhy-
drase IX (CA IX), which is regulated by hypoxia and plays a
role in chemoresistance (p  0.007); VEGFC (p  0.03);
neurotrophic tyrosine receptor kinase 1 (p  0.04); fibronec-
tin (p  0.002); insulin receptor (p  0.03). In the multivar-
iate analysis of survival, CSF1, EGFR and CA IX, and tumor
size emerged as significant variables.
The validation of these five-gene and three-gene signa-
tures was performed in tumors from an independent cohort.37
From 2000 to 2005, freshly frozen primary tumor specimens
were obtained from 142 patients. Eighty percent of them had
stage I and stage II; 66% had SCC and 33% adenocarcinoma.
Expression of genes included in the five-gene signature
(MMD, ERBB3, LCK, STAT1, and DUSP6) and the three-
gene signature (CSF1, EGFR, and CA IX) was assessed by
quantitative RT-PCR. Risk scores were used to classify
patients into high or low risk according to the expression of
the genes in the two signatures. All genes included in the
five-gene signature were more highly expressed in adenocar-
cinoma than in SCC. According to the original risk score for
the five-gene signature, median survival (MS) for low-risk
patients was not reached, whereas it was 29.7 months for high
risk (p  0.22). However, using the adjusted risk score for
SCC, MS for low-risk patients was 63 months versus 24
months for high-risk patients (p  0.003). Using the adjusted
risk score for adenocarcinoma, MS for low-risk patients was
not reached, whereas it was 46.2 months for high-risk patients
(p  0.006). According to the risk score for the three-gene
signature, MS for high-risk patients was 41 months versus
62.4 months for low-risk patients (p  0.009). For stage I to
II SCC patients, MS in low-risk patients was not reached,
whereas it was 34 months for high risk (p  0.05). For
adenocarcinoma patients, MS was not reached for low-risk
patients, whereas it was 61.2 months for high-risk ones (p 
0.04). The authors concluded that the five-gene signature is
highly predictive of survival when adjusted for histology,
whereas the three-gene signature is predictive of survival
without adjustment for histology. These gene signatures can
be useful for selecting high-risk patients for adjuvant chemo-
therapy.
Finally, in another study presented at 2008 ASCO
Annual Meeting, gene expression profiling was performed on
RNA isolated from tumor tissues of 133 (62 on observation
and 71 on chemotherapy) JBR.10 patients.38 JBR.107 is a
North American phase III Intergroup trial led by the National
Cancer Institute of Canada Clinical Trials Group (NCIC
CTG), in which 482 patients with completely resected stages
IB and II—excluding T3N0-NSCLC were randomly assigned
to receive four cycles of adjuvant cisplatin plus vinorelbine or
observation alone. Chemotherapy-treated patients enjoyed a
significant survival advantage (HR, 0.70; p 0.03), although
a significant interaction with stage was seen, with benefit
limited to stage II patients.
Authors identified a prognostic 15-gene expression sig-
nature that can classify surgery only patients into risk groups
with significantly different survival outcomes. The prognostic
signature separated the 62 observation patients into groups
with high (n  33) and low risk (n  29) for death (HR for
high/low risk, 15.02; 95% CI, 5.12–44.04; p  0.0001). It
had prognostic value both in stage IB (n  34) (HR, 13.32;
95% CI, 2.86–62.11; p  0.0001) and stage II observation
patients (n  28) (HR, 13.47; 95% CI, 3.00–60.43; p 
0.0001). But it had not prognostic value in chemotherapy-
treated patients (n 71) (HR for high/low risk, 1.15; 95% CI,
0.56–2.37; p  0.6942). The validation of the genetic profile
in five independent public gene expression datasets (stage
I–II patients, total n  372) showed that it had prognostic
value in observation patients (HR for high/low risk, 3.21;
95% CI, 1.69–6.11; p 0.0002), but not in treated ones (HR,
1.10; 95% CI, 0.47–2.53; p  0.8294). The predictive value
of the 15-gene expression signature for benefit from adjuvant
chemotherapy was also tested; chemotherapy significantly
reduces the risk of death in JBR.10 high-risk patients (n 
67) (HR, 0.33; 95% CI, 0.17–0.63; p  0.0005) but patients
with the low-risk profile (n 66) have a worse outcome from
this adjuvant treatment (HR, 3.67; 95% CI, 1.22–11.06; p 
0.0133). Interaction of chemotherapy and expression signa-
ture was highly significant (p  0.0001). If the 15-gene
signature is validated by further testing, it may improve the
current method for deciding which patients should receive
adjuvant chemotherapy.
EXCISION REPAIR CROSSCOMPLEMENTATION
GROUP 1 EXPRESSION
Clinical trials have tested the ability of adjuvant che-
motherapy to improve survival after complete resection of
NSCLC. The IALT5 demonstrated with a 4.7-year follow-up
an absolute benefit of 4.1% in 5-years OS among 1867
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patients with completely resected NSCLC stages I through III
who were randomly assigned to receive either cisplatin plus
an additional drug (etoposide or a vinca alkaloid) or to be
observed only. An updated interim analysis was presented at
the 2008 ASCO Annual Meeting.39 At a median follow-up of
7.5 months, there was a beneficial effect on disease-free
survival (DFS) (HR, 0.88; 95% CI, 0.78–0.98; p 0.02) and
a nonstatistically significant trend toward improved OS (HR,
0.91; 95% CI, 0.81–1.02; p  0.10) in patients who had
received adjuvant chemotherapy. However, there was a sig-
nificant difference between the results of OS before and after
5 years (HR, 0.86; 95% CI, 0.76–0.97; p  0.01 versus HR,
1.45; 95% CI, 1.02–2.07; p  0.04; p value for interaction
0.006). DFS benefit was also different according to the
follow-up duration (first 5 years: HR, 0.85; p  0.006; after
5 years: HR, 1.33; p  0.16; p value for interaction 0.04).
However, no validated clinical or biological predictor of
benefit from chemotherapy was identified in this trial. The IALT
Biology (IALT Bio) study40 was subsequently designed to
examine whether tumor markers could be used to predict a
survival benefit from adjuvant cisplatin-based chemotherapy
between patients who had enrolled in the IALT study.
DNA repair mechanisms are important in the resistance
to cisplatin. The destruction of cells by cisplatin requires the
binding of the drug to DNA and the creation of platinum-
DNA adducts. Some of these adducts establish covalent
crosslinking between DNA strands, thereby inhibiting DNA
replication. Nucleotide excision repair has a central role in
DNA repair and is associated with resistance to platinum-
based chemotherapy.41 The excision repair crosscomplemen-
tation group 1 (ERCC1) enzyme plays a rate-limiting role in
the nucleotide excision repair pathway that recognizes and
removes cisplatin-induced DNA adducts.42 ERCC1 is also
important in the repair of interstrand crosslinks in DNA and
in recombination processes.43,44
For more than a decade, small, retrospective clinical
studies have repeatedly reported an association between low
levels of expression of ERCC1 mRNA in several solid tumors
and improved clinical outcome among patients treated with
platinum-containing regimens.45–47 In particular, it has been
reported that the expression of ERCC1 mRNA predicts a
response to chemotherapy in advanced NSCLC.48 Further-
more, two common polymorphisms of the ERCC1 gene
(codon 118 C/T and C8092A) have been correlated with the
response to platinum-based chemotherapy in colorectal can-
cer49 and NSCLC.45 These polymorphisms are mainly asso-
ciated with lower rates of translation of the ERCC1 gene,
which results in low levels of the protein in nuclei. Previ-
ous studies50 have also suggested that, in the absence of
adjuvant chemotherapy, ERCC-1 is a prognostic factor of
better outcome.
These data led authors of the IALT-Bio study to hy-
pothesize that ERCC1 expression could predict a survival
benefit from cisplatin-based adjuvant chemotherapy in com-
pletely resected NSCLC. They used immunohistochemical
analysis to determine the expression of this protein in 761
paraffin-embedded tumor samples from patients enrolled in
the IALT-study, 389 (51%) of whom were assigned to the
chemotherapy group and 372 (49%) to the control group.
ERCC1 expression was positive in 335 (44%) and
negative in 426 (56%) patients. A multivariate logistic model
showed that the expression of this enzyme was significantly
correlated with age (p  0.03; less common in patients
younger than 55 years of age than in patients 55–64 years of
age), histologic type (p  0.001; less common in adenocar-
cinomas than in SCC), and pleural invasion (p  0.01; less
common in the absence than in the presence of pleural
invasion). A benefit from cisplatin-based adjuvant chemo-
therapy was associated with the absence of ERCC1 (test for
interaction, p  0.009). Adjuvant treatment, when compared
with observation, significantly prolonged OS among patients
with ERCC1-negative tumors (HR for death, 0.65; 95% CI,
0.50–0.86; p  0.002) but not among patients with ERCC-1
positive tumors (adjusted HR for death, 1.14; 95% CI, 0.84–
1.55; p  0.40). The 5-year OS rates among patients with
ERCC1-negative tumors were 47% (95% CI, 40–55%) in the
chemotherapy group and 39% (95% CI, 32–47%) in the control
group. Median OS was 14 months longer in the adjuvant
chemotherapy group (56 months) than in the control group (42
months) (Table 1). DFS among patients with ERCC1-nega-
tive tumors was also longer in the chemotherapy group than
in the control one (adjusted HR for recurrence and death,
0.65; 95% CI, 0.50–0.85; p  0.001).
However, in the control group, the 5-year OS rate was
significantly higher among patients with ERCC1-positive
tumors than among patients with ERCC1-negative tumors
(HR, 0.66; 95% CI, 0.49–0.90; p  0.009). This finding is in
contrast to the results observed in patients who received
adjuvant chemotherapy and favors the interpretation that the
TABLE 1. Overall Survival According to ERCC-1 Expression in the Chemotherapy and
Control Group of IALT-Bio Study
Chemotherapy (n  399)
5-yr Survival Rate
Median Survival
Control Group (n  372)
5-yr Survival Rate
Median Survival
Hazard Ratioa
for Death
CT vs. No CT
ERCC1-negative tumors
(n  426)
47% (40–55%) 39% (32–47%) 0.65 (0.50–0.86)
56 mo 42 mo p  0.002
ERCC1-positive tumors
(n  335)
40% (32–49%) 46% (37–55%) 1.14 (0.84–1.55)
50 mo 55 mo p  0.40
a Adjusted on sex, age, stage, histology, and pleural invasion.
CT, chemotherapy; IALT, International Adjuvant Lung Cancer Trial; ERCC, excision repair crosscomplementation group.
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presence or absence of ERCC1 is a determinant of the
sensitivity of NSCLC cells to platinum.
In conclusion, if these results are confirmed by large,
independent, and prospective studies, determination of ERCC1
expression in NSCLC cells before chemotherapy could be
widely applicable as an independent predictor of the effect of
adjuvant chemotherapy; patients with ERCC1-negative tumors
derived a substantial benefit from adjuvant cisplatin-based che-
motherapy, when compared with ERCC1-positive tumors.
RIBONUCLEOTIDE REDUCTASE SUBUNIT M1
EXPRESSION
Ribonucleotide reductase subunit M1 (RRM1), the gene
that encodes the regulatory subunit of ribonucleotide reductase is
located on chromosome segment 11p15.5, a region with a
frequent loss of heterozygosity in NSCLC.51 RRM1 is involved
in tumor invasiveness and metastasis.52,53 Phospathase and ten-
sin homologue (PTEN), a bifunctional phospathase that regu-
lates cellular signaling, survival, and migration,54 is thought to
mediate these effects of RRM1. The increased expression of
RRM1 decreases the formation of metastases, inhibits the
development of carcinogen-induced lung tumors, and pro-
longs survival in tumor-bearing mice.52,53,55 In previous stud-
ies, an association between high expression of RRM1, as
determined by quantitative RT-PCR, and prolonged survival
has been reported in patients with NSCLC.56 RRM1 is also
the predominant cellular determinant of the efficacy of the
nucleoside analogue gemcitabine.57,58
Dr. Bepler’s group performed a study to validate RRM1
as a marker of the clinical outcome in a large cohort of
patients with NSCLC.59 Authors describe an immunohisto-
chemical method for the determination of RRM1 expression
in histologic specimens of 187 patients with early-stage
NSCLC who had received only surgical treatment. Patients
were eligible for inclusion in the study if they had an
adenocarcinoma, SCC, or large-cell carcinoma; had under-
gone a complete resection of the tumor; and had stage I
disease by pathologic staging. None of them received any
form of preoperative or adjuvant therapy. The primary ob-
jective was to determine the association between RRM1
expression in the tumor and survival. Secondary objectives
were to assess the associations between the expression of
RRM1 and ERCC1, between RRM1 and PTEN, and between
mRNA and protein levels of RRM1.
This study showed a significant correlation between the
RRM1 protein and its mRNA (p  0.004). High expression
of RRM1 protein is associated with better outcome. The
median DFS exceeded 120 months in the group of patients
with tumors that had high expression of RRM1 and was 54.5
months in the group with low expression of RRM1 (HR for
disease progression in the high-expression group, 0.46; p 
0.004). The OS was more than 120 months for patients with
tumors with high expression of RRM1 and 60.2 months for
those with low expression of RRM1 (HR for death, 0.61; p
0.02). In a multivariate analysis that included RRM1 expres-
sion, tumor stage, ECOG performance status, sex, and smok-
ing status, RRM1 was the only variable that was significantly
associated with DFS (p  0.03); the association with OS,
however, was not statistically significant (p  0.11). There
was neither significant association between RRM1 expression
and tumor stage, histologic type, age, sex, ECOG perfor-
mance status, absence or presence of weight loss, and smok-
ing status.
On the other hand, the scores for RRM1 were not corre-
lated with those for PTEN (p 0.07) and PTEN expression was
not significantly associated with survival. However, RRM1
scores were significantly correlated with ERCC1 (p 0.001),
and ERCC1 expression was associated with survival (p 
0.11 for DFS and p  0.01 for OS). So, authors grouped the
184 patients with scores for both proteins into four categories:
55 patients had tumors with high expression of both proteins
(high/high), 54 had low expression of both (low/low), 38 had
high RRM1 expression and low ERCC1 expression (high/
low), and 37 had low RRM1 and high ERCC1 (low/high).
The coordinate high expression of RRM1 and ERCC1 defines a
subgroup of patients with an excellent outcome, with a median
DFS and a median OS of more than 120 months, which were
significantly longer than those for the patients in the other groups
(p  0.01 for DFS, and p  0.02 for OS) (Figure 3).
The apparent lack of an association between RRM1
and PTEN contrasts with the previously reported positive
correlation between these genes at the RNA level.55 This
discrepancy may be due to differential, posttranslational
processing or compartmentalization for PTEN and RRM1
or to technical issues.60,61
In conclusion, given that high levels of expression of both
ERCC1 and RRM1 are associated with long survival among
patients with completely resected lung cancer and are also
associated with a poor response to chemotherapy containing
gemcitabine and platinum, a trial comparing the current standard
of care with adjuvant treatment selected on the basis of RRM1
and ERCC1 expression seems to be warranted.
BREAST CANCER 1 EXPRESSION
Breast cancer 1 (BRCA1) plays a crucial role in DNA
repair and it is implicated in transcription-coupled nucleotide
excision repair (TC-NER), and modulation of its expression
leads to modification of TC-NER and hence to radio- and
chemoresistance.62 BRCA1 is also involved in homologous
recombination repair and nonhomologous end joining, in
response to DNA damage.63 In addition, it is a component of
a large DNA repair complex termed the BRCA1-associated
genome surveillance complex, which contains a number of
mismatch repair proteins, indicating a potential role for
BRCA1 in mismatch repair.62,63 BRCA1 may also be a
regulator of mitotic spindle assembly, as BRCA1 and -tu-
bulin colocalize to the microtubules of the mitotic spindle and
to the centrosomes.64 Finally, enhanced BRCA1 expression
has been linked to apoptosis through the c-Jun N-terminal
kinase pathway,65 which is activated by cisplatin-induced
DNA damage; inhibition of this pathway increased cisplatin
sensitivity in cell lines.66 Decreased BRCA1 mRNA expres-
sion in a breast cancer cell line led to greater sensitivity to
cisplatin and etoposide, but to a greater resistance to the
microtubule-interfering agents paclitaxel and vincristine.67
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On the basis of the evidence for the role of BRCA1 in
breast and ovarian cancers, Taron et al.68 examined the
potential role of BRCA1 mRNA expression in predicting
differential chemotherapy sensitivity in NSCLC. They used
quantitative RT-PCR to determine BRCA1 mRNA levels in
55 surgically resected tumors of NSCLC patients who had
received neoadjuvant gemcitabine/cisplatin chemotherapy,
and divided the gene expression values into quartiles. When
results were correlated with outcome, two cutoffs were ob-
served: patients with levels 0.61 had better outcome, and
those2.45 had poorer outcome. MS was not reached for the
15 patients in the bottom quartile, whereas for the 28 in the
two middle quartiles, it was 37.8 months (95% CI, 10.6–65),
and for the 12 patients in the top quartile, it was 12.7 months
(95% CI, 0.28–28.8) (p  0.01). Moreover, when patients
were stratified by pathologic stage, those in the bottom
quartile had a decreased risk of death (HR, 0.206; 95% CI,
0.05–0.83; p  0.026) compared with those in the top
quartile, and those in the two middle quartiles also had a
decreased risk of death (HR, 0.294; 95% CI, 0.10–0.83; p 
0.020) compared with those in the top quartile.
In a recent study Rosell et al.69,70 hypothesized that
altered mRNA expression in nine genes could help to identify
patients with a higher risk of recurrence within each stage of
the disease. They chose to examine the following genes,
based on previous reports of their predictive value: ERCC1,
which is involved in keeping genetic alterations to a mini-
mum45; myeloid zinc finger 1 (MZF1),71–73 which mediates
ERCC1 expression; Twist1,74,75 which regulates N-cadherin
expression and contributes to metastasis by promoting epi-
thelial-mesenchymal transition; thioredoxin 1 (TRX1),76,77 a
redox protein overexpressed in NSCLC that is correlated with
poor prognosis; the RRM1,59,78,79 regulated by TRX1, which
induces HIF-1 and VEGF; tyrosyl-DNA-phosphodiesterasa
(Tdp1),80–82 which is overexpressed in NSCLC; nuclear fac-
tor of activated T cells,83,84 which promotes carcinoma inva-
sion in vitro; the human homolog of yeast budding uninhib-
ited by benzimidazole 1,85–87 which confers poor survival in
colorectal cancer and BRCA1,68 which regulates the expres-
sion of budding uninhibited by benzimidazole 1.
To shed light on the prognostic value of these genes,
authors examined their expression by quantitative RT-PCR in
frozen lung cancer tissue specimens from 126 chemonaive
NSCLC patients who had undergone complete surgical re-
section between 2000 and 2004 and correlated the results
with survival.
The patients were 98 men and 28 women, with age at
diagnosis ranging from 37 to 77 years (median age, 64 years).
Ninety-three patients (73.8%) had SCC and 20 (22.2%)
adenocarcinomas. In relation with pathologic stage, 18 pa-
FIGURE 3. Kaplan-Meier estimates
of disease-free survival (A) and over-
all survival (B) among patients with
stage I NSCLC according to ERCC1
and RRM1 expression levels.
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tients (14.3%) had stage IA disease, 53 (42.1%) stage IB, 35
(26.2%) stage II, and 22 (17.5%) stage IIIA. One hundred and
twenty-two patients underwent formal pulmonary lobectomy
or more, with systematic ipsilateral mediastinal lymph node
dissection; the four remaining patients underwent segmentec-
tomy due to poor pulmonary reserve. None of the patients
received adjuvant chemotherapy. The BCRA1 prognostic
value was validated in an independent cohort of 58 stage
IB–IIB NSCLC patients.
There were significant differences in expression ac-
cording to histology for all genes except nuclear factor of
activated T cells, with higher levels observed in SCC than in
adenocarcinomas. There were no differences in gene expres-
sion according to stage or tumor size (4 versus 4 cm). A
strong correlation was observed between expression levels of
different genes, for example, between levels of TRX and
RRM1 (  0.52; p  0.0003) and between ERCC1 and
BRCA1 (  0.62; p  0.0001).
With a median follow-up of 29.7 months, overall event-
free survival (EFS) and MS have not been reached. When
EFS and MS was analyzed according to expression levels of
the nine genes, TRX and BRCA1 showed significant differ-
ences (Figure 4). EFS for 21 patients with low TRX levels
has not been reached, whereas it was 32 months (95% CI) for
the remaining 93 patients with high levels (p  0.02). For 77
patients with low levels of BRCA1, EFS has not been
reached, whereas it was 22 months (95% CI, 14.9–29
months) for those with high levels (p  0.04). MS for 24
patients with low TRX levels has not been reached, whereas
it was 39 months for the remaining 101 patients with high
levels (p  0.03). For 83 patients with low levels of BRCA1,
MS has not been reached, whereas it was 29 months (95% CI,
22.2–35.7 months) for those with high levels (p  0.04). MS
according to expression of the other seven genes are shown in
Table 2. Expression levels of these genes did not have
prognostic value for the entire study population, although
low-MZF1 levels showed a trend toward better outcome. For
56 patients with low levels of MZF1, MS has not been
reached, whereas it was 33 months (95% CI, 21.9–44.1
months) for the 66 patients with high levels (p  0.05).
Further study is warranted in this area to elucidate the
predictive role of these NER-related genes and to correctly
customize treatments.
FIGURE 4. Event-free and median survival according to expression of TRX (A and C) and BRCA1 (B and D).
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When only stage I patients were examined, EFS was
significantly different according to expression levels of
MZF1 and BRCA1, and MS was significantly different ac-
cording to expression levels of ERCC1, MZF1, Twist, and
BRCA1. These findings highlight the potential role of
ERCC1 and MZF1, which are highly correlated with BRCA1,
as strong prognostic markers in stage I NSCLC. Not unex-
pectedly, however, considering the high correlation between
the expression levels of these three genes, when they were
combined, no further improvement over the prognostic value
of BRCA1 alone was observed.
In a multivariate Cox model, pathologic stage IIIA
(HR, 7.91; 95% CI, 2.27–27.54; p  0.001) and BRCA1
mRNA expression (HR, 1.98; 95% CI, 1.11–6; p  0.02)
were the only independent prognostic factors for OS. In the
validation cohort, the HR for patients with high levels of
BRCA1 was 2.4 (95% CI, 1.01–5.92; p  0.04) according to
the Cox proportional hazards model. There were no stage
IIIA patients in this cohort.
In conclusion, overexpression of BRCA1 mRNA was
strongly associated with poor survival in NSCLC patients,
and the validation of this finding in an independent data set
further strengthened this association. Patients whose tumors
had high BRCA1 expression had significantly worse survival
and should be candidates for adjuvant chemotherapy.
Results of previous studies of ERCC140 (stage I–IIIA)
and RRM159 (stage I) protein expression are in contrast to the
findings reported here. It is not clear why low ERCC1 or RRM1
expression was found to confer poor survival in these studies,
whereas in the present study high expression of ERCC1—and
specially MZF1—had a detrimental effect in stage I and low
expression was beneficial. These conflicting results highlight the
need for further research. Patients should be stratified according
to the expression of these genes in prospective clinical trials of
adjuvant chemotherapy to clarify their role.
On the other hand, in vitro studies have shown that
BRCA1 can regulate differential sensitivity to different
classes of chemotherapy agents.88 The absence of BRCA1
results in high sensitivity to cisplatin, whereas its presence
increases sensitivity to antimicrotubule agents. Moreover,
some reports have demonstrated that patients with high-
BRCA1 levels attained longer survival when treated with
taxane-based therapy.88,89 Based on this results, the Spanish
Lung Cancer Group performed an adjuvant trial90 in which
adjuvant chemotherapy was customized based on BRCA1
mRNA levels in 84 completely resected N1 and N2 NSCLC
patients. Eleven patients with high-BRCA1 levels received
docetaxel, 29 patients with intermediate BRCA1 levels re-
ceived docetaxel/cisplatin and 44 patients with low-BRCA1
levels received cisplatin/gemcitabine. At the time of the
analysis, MS has not been reached in patients with high or
intermediate BRCA1 levels, whereas it is 25.6 months in
patients with low levels (p  0.04). In a multivariate analysis
for survival in all 84 patients, the HR were 5.23 for patients
with high-BRCA1 levels (p  0.07) and 3.57 for patients
with tumor size 4 cm (p  0.07).
Forty-two N2 patients were included in the study, 18 of
which were treated with postoperative radiotherapy. In rela-
tion with BRCA1 expression, 24 patients had low-BRCA1
mRNA levels and 15 intermediate or high levels. In the
multivariate analysis, postoperative radiotherapy was a sta-
tistically significant good-prognostic factor (HR, 0.12; 95%
CI, 0.02–0.89; p  0.04), whereas intermediate or high-
BRCA1 levels were associated with worse outcome (HR,
22.43; 95% CI, 2.02–248.62; p  0.01).
In conclusion, single-agent docetaxel has no detrimen-
tal effect on survival in comparison with docetaxel/cisplatin.
Moreover, high-BRCA1 mRNA expression could be a poor
prognostic marker. These results are not definitive and re-
quire confirmation. If this hypothesis is validated in pro-
spective clinical trials, patients with the highest BRCA1
expression levels should receive antimicrotubule, nonplati-
num-based adjuvant chemotherapy.
The influence of XPG mRNA levels on the effect of
BRCA1 mRNA levels in prognosis of early NSCLC has been
shown in another study presented at the 2008 American
Society of Clinical Oncology Annual Meeting.91 Xeroderma
pigmentosum complementation group G (XPG) belongs to
the flap endonuclease 1 family of nucleases. XPG expression
is correlated with cellular nucleotide excision repair activity
TABLE 2. Median Survival According to Gene Expression
Na Median Survival (mo) 95% CI p
ERCC1 0.89
1.24 61 NR —
1.24 62 39.5 —
MZF1 0.05
0.5 56 NR —
0.5 66 33 21.9–44.1
Twist 0.39
7.75 61 NR —
7.75 61 NR —
RRM1 0.11
1.65 61 NR —
1.65 60 33.9 24–43.9
TRX 0.03
0.8 24 NR —
0.8 101 39 —
Tdp1 0.88
1.57 60 NR —
1.57 61 41.3 —
NFAT 0.51
0.46 61 NR —
0.46 61 33.9 —
BRCA1 0.01
5 83 NR —
5 40 29 22.2–35.7
BubR1 0.41
12.28 61 NR —
12.28 61 36.7 —
NR, not reached; ERCC1, excision repair crosscomplementation group 1; MZF1,
myeloid zinc finger 1; RRM1, ribonucleotide reductase subunit M1; TRX, thioredoxin;
Tdp1, tyrosyl-DNA-phosphodiesterasa; NFAT, nuclear factor of activated T-cells;
BubR1, human homolog of yeast budding uninhibited by benzimidazole 1; BRCA1,
breast cancer 1.
aNumber of patients.
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009 Prognostic and Predictive Markers
Copyright © 2009 by the International Association for the Study of Lung Cancer 899
and may be a useful marker to predict sensitivity to platinum
compounds. In this study BRCA1, ERCC1, RRM1, and XPG
transcripts were examined by quantitative PCR in tumors of
54 resected stage I and stage II NSCLC patients. Median DFS
was 40 months for stage IA, not reached for stage IB, and 25
months for stage II. DFS was not reached in 18 patients with
low-BRCA1 mRNA levels, whereas 37 patients with high-
BRCA1 mRNA levels had a DFS of 22.4 months (p  0.02).
In contrast, patients with high XPG had a 51-months DFS,
whereas patients with low XPG had a 26-months DFS. When
BRCA1 and XPG levels were considered jointly, DFS was
not reached for patients with low levels of BRCA1 regardless
of whether XPG was high (10 patients) or low (17 patients).
However, for patients with high-BRCA1 levels, DFS was
shorter for 10 patients with low XPG (16.4 months) than for 17
patients with high XPG (26 months). Authors concluded that
high-BRCA1 mRNA expression confers poor prognosis in early
NSCLC and the combination of high BRCA1 plus low XPG
expression still further increases the risk of shorter DFS.
CLASS III -TUBULIN EXPRESSION
Among the described mechanisms of resistance to antitu-
bulin agents, class III -tubulin (bTubIII) overexpression is of
particular interest. Many preclinical studies have shown high
levels of expression of bTubIII are associated with paclitaxel
resistance in human cancer cells lines (lung,92 ovarian,93 pros-
tate,94 and breast92) and with docetaxel resistance in human
pancreatic cancer cell lines.95 Similar results have been ob-
tained for vinca alkaloids.96,97 The mechanistic involvement
of bTubIII overexpression in the determination of resistance
remains open to debate. Current hypotheses are that these
alterations could alter drug binding to the tubulin dimer,98 or,
alternatively, that the microtubule contained in the tumor
cells could have different intrinsic dynamic properties and
thus might be less sensitive to antitubulin agents.99,100
Several studies have shown that levels of expression of
bTubIII could possess predictive value for response and
outcome in patients with advanced NSCLC receiving tubulin-
binding agents.78,101–103 Rosell et al.78 showed that patients
with low levels of bTubIII mRNA had better response rates
when treated with carboplatin plus paclitaxel and longer time
to progression when given vinorelbine plus gemcitabine com-
pared with individuals with high levels of such mRNA. By
contrast, levels of bTubIII mRNA were not found to be
predictive in patients receiving a gemcitabine/cisplatin regi-
men. It has also been shown that high level of expression of
bTubIII in tumor cells, assessed by a semiquantitative immu-
nohistochemical assay, was associated with a lower response
rate and a poor clinical outcome in advanced NSCLC patients
receiving vinorelbine-based chemotherapy.101 In another
study of 19 patients102 receiving taxane-based regimens,
progression-free survival was shorter in patients whose tu-
mors expressed high levels of bTubIII. Using a similar
approach, expression of bTubIII was examined in 91 tumor
samples obtained from patients with stage III and stage IV
NSCLC, including 47 who received paclitaxel-based regi-
mens and 44 who received regimens without tubulin-binding
agents.103 This retrospective study showed high levels of
bTubIII were associated with a lower response rate and
shorter survival in patients with advanced NSCLC receiving
paclitaxel, but not in patients receiving regimens without
tubulin-binding agents.
To determine whether bTubIII might be a useful marker
in early NSCLC patients undergoing adjuvant chemotherapy
with a vinorelbine-based regimen, Se`ve et al.104 assessed the
levels of bTubIII in tumor samples from patients treated on
the NCIC-CTG JBR.10 study7 and correlated them with
outcome in both treated and control patients groups.
A semiquantitative immunohistochemical assay for class
bTubIII was done on primary tumor tissues available for 265
(55%) of the 482 patients in the trial. High-bTubIII expressors
(n  133) included more women (42% versus 30%; p  0.04),
fewer with squamous histology (25% versus 48%; p  0.001),
more with RAS mutations (31% versus 20%; p  0.05), more
patients 60 years old (53% versus 42%; p  0.09), and more
PS1 patients (58% versus 47%; p  0.09) compared with the
low-tubulin expressors (n  132). Gender, stage, type of lung
resection, and chemotherapy treatment assignment were not
related to bTubIII expression.
High versus low-bTubIII expression was associated
with inferior outcome for the entire study population. The
result was statistically significant for RFS (HR, 1.52; 95% CI,
1.05–2.22; p  0.03) and a similar trend was seen for OS
(HR, 1.39; 95% CI, 0.96–2.01; p  0.08). But the value of
tubulin expression in predicting RFS and OS seemed to be
largely confined to those patients assigned to the observation
arm of JBR.10. High-bTubIII expression was associated with
poorer survival in patients treated with surgery alone (RFS:
HR, 1.92; 95% CI, 1.16–3.18; p  0.01; OS: HR, 1.72; 95%
CI, 1.02–2.88; p  0.04). Tubulin expression was not a
statistically significant predictor of outcome in the patients
assigned to receive chemotherapy (RFS: HR, 1.10; 95% CI,
0.62–1.95; p  0.75; OS: HR, 1.11; 95% CI, 0.65–1.88; p 
0.7). Cox regression stratified by treatment arm was used to
examine the relationship between bTubIII expression and
RFS or OS after adjusting for other prognostic factors. In this
type of model, high-bTubIII expression remained as a signif-
icant adverse prognostic factor for RFS (HR, 1.78; 95% CI,
1.06–3.00; p 0.03). Similar results were seen in a model of
OS (HR, 1.42; 95% CI, 0.97–2.09; p  0.07).
This study also compared the benefits of adjuvant
chemotherapy in high versus low-bTubIII expressors (Figure
5). In the low-bTubIII group (n  132), no significant
difference in RFS (HR, 0.78; 95% CI, 0.44–1.37; p  0.4) or
OS (HR, 1.00; 95% CI, 0.57–1.75; p  0.99) was seen in
between patients assigned to chemotherapy (n  72) and
observation (n  60). However, in the high-bTubIII group
(n  133), patients receiving chemotherapy (n  68) had
significantly improved RFS (HR, 0.45; 95% CI, 0.27–0.75;
p  0.002) and a trend toward improved OS (HR, 0.64; 95%
CI, 0.39–1.04; p  0.07) compared with patients in the
observation arm (n  65). But in a Cox regression analysis,
the interaction between levels of bTubIII and chemotherapy
treatment predicting RFS and OS did not reach statistical
significance (p  0.15 for RFS; p  0.25 for OS).
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In conclusion, the results of this study suggest that
high-bTubIII expression in resected NSCLC is associated
with poorer survival in the absence of adjuvant chemotherapy
treatment but not in patients who receive adjuvant chemo-
therapy. These findings suggest that adjuvant cisplatin/vi-
norelbine chemotherapy can overcome the adverse biology of
cancers that express higher amounts of bTubIII. Furthermore,
adjuvant chemotherapy significantly prolonged the RFS and
OS in the high-bTubIII expressors, but its effect was not clear
for the low-bTubIII expressors in this study. High-bTubIII ex-
pression is associated not only with a higher risk of relapse after
surgery alone but also with a higher probability of benefit from
adjuvant cisplatin plus vinorelbine chemotherapy.
The adverse prognostic significance of high-bTubIII
expression observed in this study is consistent with prior
published reports in the setting of advanced NSCLC. How-
ever, this report is contrary to the data from advanced
NSCLC about the value of bTubIII expression in predicting
benefit from chemotherapy. In the setting of advanced dis-
ease, low-bTubIII expression is associated with a higher
objective response rate to chemotherapy containing the anti-
microtubule agents but does not seem to predict response to
regimens that do not target microtubules.78,101–103 On the
other hand, the results of the present study suggest that in
early lung cancer, it is the patients with high-bTubIII expres-
sion that are most likely to benefit from adjuvant cisplatin and
vinorelbine. It is possible that all the studies are correct and
that bTubIII has differential predictive implications in early
versus advanced NSCLC. This discrepancy between the met-
astatic and adjuvant setting is not without precedent. In
colorectal cancer, the relationship between thymidylate syn-
thase and benefit from chemotherapy differs between opera-
ble and advanced disease.105,106 The reason for the current
discrepancy is as yet unexplained.
On the basis of previous results, Reiman et al.107 tried
to verify that high-bTubIII expression might correlate with
greater benefit from adjuvant chemotherapy in an analysis of
tumor tissues from 737 patients in the IALT trial. Because
some chemotherapy regimens in this trial did not include an
antitubulin agent, authors also tested the hypothesis that the
value of bTubIII expression in predicting benefit from che-
motherapy was specific to antitubulin containing regimens.
High-bTubIII expression significantly correlated with adeno-
carcinoma histology (p  0.0001), lymphatic (p  0.03) and
vascular invasion (p  0.01), and DFS (HR, 1.26; 95% CI,
1.01–1.58; p  0.04), with a similar trend in OS (p  0.12).
There was no significant interaction between bTubIII status
and treatment assignment in predicting DFS (HR for chemo-
therapy effect in high versus low-bTubIII groups, 0.92; p 
0.71) or OS (HR, 1.01; p  0.98), when the analysis was
restricted to antitubulin containing regimens (DFS: HR, 0.90;
p  0.71; OS: HR, 0.93; p  0.82). In conclusion, high-
bTubIII expression is also an adverse prognostic factor in
IALT, in concordance with prior observations in JBR.10.
FIGURE 5. A, Relapse-free survival and overall survival curves for low-tubulin expressors according to treatment assignment;
B, Relapse-free survival and overall survival curves for high-tubulin expressors according to treatment assignment. vin/cisp, vi-
norelbine/cisplatin.
Journal of Thoracic Oncology • Volume 4, Number 7, July 2009 Prognostic and Predictive Markers
Copyright © 2009 by the International Association for the Study of Lung Cancer 901
However, unlike what was suggested in JBR.10, in IALT
bTubIII expression did not correlate with benefit from adju-
vant chemotherapy.
CELL CYCLE REGULATORS
P53 and RAS are multifunctional proteins that play key
roles in regulating cell cycle progression, apoptosis, gene
transcription, response to stress, and DNA repair.108–110 They
are the most extensively investigated prognostic markers in
NSCLC, with each having more than 50 reported studies.
Although meta-analyses generally have indicated that aber-
rations of these genes are weak prognostic markers of poorer
outcome in NSCLC, results from individual studies have
been inconsistent.110–113 Meta-analysis cannot eliminate po-
tential biases that may exist in published data,114 making it
imperative that promising markers identified in meta-analyses
be confirmed prospectively or retrospectively in large phase
III randomized trials.115,116 Moreover, because p53 is an
important factor in the regulation and initiation of DNA
repair, aberrations in p53 expression may also affect response
to chemotherapy.117
In a recently published study,118 authors evaluated the
prognostic and predictive value of p53 and RAS gene mutations
and p53 protein overexpression using tumor samples from
NCIC-CTG JBR.10 trial.7 P53 protein expression was evaluated
by immunohistory (IHC) in paraffin-embedded tissue sections of
253 patients. The prevalence of p53 overexpression was 52%
(132 patients). P53 positive tumors were more frequent in men,
SCC, and tumors with wild-type RAS. In the observation arm,
patients with p53-positive tumors had significantly shorter sur-
vival than did those with p53-negative tumors (p  0.03; HR,
1.89; 95% CI, 1.07–3.34) indicating that p53 protein overex-
pression is a significant marker of poor prognosis, even after
multivariate adjustment for other potential prognostic factors
(p  0.02).
However, patients with p53-positive tumors derived
significant benefit from adjuvant chemotherapy (HR, 0.54;
95% CI, 0.32–0.92; p  0.02), whereas patients with p53
negative tumors had not (HR, 1.40; 95% CI, 0.78–2.52; p 
0.26) (Figure 6). In the multivariate model the interaction of
chemotherapy and p53 overexpression remained significant
(p  0.05). Furthermore, this significant interaction was
maintained even when multivariate regression modeling was
applied to all 482 patients in JBR.10, including those who did
not have p53 IHC (p  0.01).
Authors also investigated exons 5 to 9 for the presence
of mutations because these constitute more than 90% of all
p53 mutations in NSCLC.110,119 They were determined by
denaturing high performance liquid chromatography and con-
firmed by sequencing. It was found that 124 (31%) of 397
patients had functional mutations, including six patients
whose tumors revealed multiple mutations. P53 mutation was
not prognostic for survival in the observation arm (HR for
mutant versus wild type, 1.15; 95% CI, 0.75–1.77; p 0.45).
Patients with p53 mutations did not derived significant sur-
vival benefit from adjuvant chemotherapy (HR, 0.78; 95%
CI, 0.46–1.32; p  0.35). For 273 patients with wild-type
p53, chemotherapy significantly prolonged survival com-
pared with observation (HR, 0.67; 95% CI, 0.46–0.98; p 
0.04), but the interaction p value in the multivariate analysis
was insignificant at 0.65.
Finally, RAS mutations were identified by allelic-spe-
cific oligonucleotide hybridation. Because JBR.10 stratified
patients according to their RAS mutation status, it was known
in more than 90% of randomly assigned patients. Authors
identified 119 mutations in 117 of 450 patients (26%), which
were significantly higher in large-cell and adenocarcinoma
and in women. RAS mutation was not a significant prognostic
marker for survival in univariate or multivariate analyses. In
333 patients with wild-type RAS, survival was significantly
prolonged with adjuvant chemotherapy compared with obser-
vation (HR, 0.69; 95% CI, 0.49–0.97; p  0.03). In contrast,
there was no apparent benefit from chemotherapy in 117
patients with RAS mutant tumors (HR, 0.95; 95% CI, 0.53–
1.71; p  0.87). However, in the multivariate model, signif-
icant interaction between chemotherapy and RAS mutation
was not detected (p  0.29).
P53 nuclear immunoreactivity in tumors had been re-
garded as a surrogate marker for the presence of p53 gene
mutation, because missense mutant p53 protein demonstrates
a longer half life than does wild-type protein.120 However,
Greenblatt et al.121 reported than in 84 studies evaluating p53
mutation and p53 protein by IHC simultaneously, the overall
sensitivity of IHC to predict p53 mutation status was 75%,
whereas the positive predictive value was only 63%. In this
study, 56 (75%) of 75 mutant p53 tumors were positive for
p53 staining, but 68 (43%) of 158 of wild-type p53 tumors
were also positive for IHC. Although a majority of IHC-
negative mutant cases could usually be accounted for by
deletion/nonsense mutations, the mechanistic basis, and bio-
logical significance of wild-type p53 protein overexpression
in tumors is less clearly understood.
Recent discoveries place increasing importance on
MDM2 and p14ARF as regulators of cellular p53 protein
levels.122 The degradation of p53 protein by the ubiquitin
pathway is mediated by its binding to MDM2, an E2 ligase,
and the expression of MDM2 mRNA and protein is nega-
tively regulated by p14ARF. The stability of mutant p53
protein in tumor cell seems more dependent on its inability to
bind MDM2,123 and the level of wild-type p53 protein is also
significantly regulated by the MDM2 expression level. Wang
et al.124 studied 94 NSCLC and identified 16 p53 mutant
tumors (17%). Although 45 tumors were p53 IHC positive,
37 overexpressed the wild-type p53 protein. Among the
latter, 35 (95%) and 34 (92%) had low expression of MDM2
and high expression of p14ARF, respectively. They reported
that overexpression of p53 and low expression of MDM2 are
poor prognostic markers. Their study provides compelling
evidence that the biological effects of p53 mutation and p53
protein overexpression may not be identical, and that the
regulation of p53-MDM2 pathway may influence the out-
come of NSCLC patients.
The regulation of expression, signaling pathways, and
biological activity of p53 is complex.108,125 It remains spec-
ulative why p53 protein expression rather than p53 mutation
imposes more aggressive clinical behavior in NSCLC. One
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hypothesis could be that high levels of p53 protein, regardless
of mutation status, are reflective of significant oncogenic
(e.g., myc, -catenin) activation pathways, leading to p14
overexpression and stabilized p53 protein.125,126 The role of
p53 mutation and/or aberrant protein expression (positive
IHC staining) in DNA repair and response to chemotherapy is
also complex and remains controversial.126 There is contra-
dictory evidence as to whether or not p53 mutation/aberrant
protein expression could affect the sensitivity of solid tumors
to anticancer agents.117,125 Results of this study indicate that
adjuvant chemotherapy seems not to be very effective in p53
mutant patients, but p53 IHC-positive tumors remain sensi-
tive to treatment. On the other hand, there is some evidence
to suggest that the disruption of p53 function could sensitize
tumor cells to the effect of chemotherapeutic drugs such as
cisplatin, whose DNA damage is repaired by nucleotide
excision pathways.127 Sensitization could possibly be caused
by an inability of p53 aberrant tumor cells to transactivate
p21 and allow DNA repair to occur, or by an interference of
tumor cellular ability to sense DNA damage or initiate/effect
DNA repair.115 The discrepancy between the role of p53
mutation and aberrant protein expression suggest that the
biological effects of these 2 p53 abnormalities are not equiv-
alent and their roles warrant further mechanistic studies.
In conclusion, of the markers assessed in this study, p53
protein overexpression is both prognostic for poorer survival
and predictive of a differentially greater survival benefit from
adjuvant chemotherapy. Although p53 and RAS wild-type
patients seem to derive greater benefit from adjuvant chemo-
therapy than do patients with p53 or RAS mutant tumors, the
differences in this study was not statistically significant.
These observations, together with those demonstrating a
differential benefit from adjuvant chemotherapy in patients
with low ERCC1 protein expression,40 suggest that the great-
est benefit from platinum-based adjuvant chemotherapy
should be in NSCLC patients with low ERCC1 but high p53
FIGURE 6. Overall survival curves of patients with p53 protein expression (immunohistochemistry) results. (A) p53 IHC re-
sults known; (B) p53 IHC results, observation; (C) p53 IHC positive; and (D) p53 IHC negative.
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protein expression. An international collaborative BIO-Lung
Adjuvant Cisplatin Evaluation study is planned to test this
hypothesis in a large cohort of patients’ samples that should
have the statistical power to test multiple markers. It seems
that we are on the threshold of molecular selection of NSCLC
patients for postoperative adjuvant chemotherapy.
Authors from the Medical University of Vienna per-
formed an study to determine whether cell cycle regulators
are of prognostic and/or predictive value in patients who were
enrolled onto the IALT trial.128 Expression of p27Kip1,
p16INK4A, cyclin D1, cyclin D3, cyclin E, and Ki-67 was
immunohistochemically assessed in tumors specimens ob-
tained from 778 IALT patients. A relationship between
p27kip1 status and benefit of cisplatin-based chemotherapy
was found (test for interaction, p  0.02). Among patients
with p27Kip1-negative tumors, cisplatin-based chemotherapy
resulted in longer OS compared with controls (HR for death
0.66, 95% CI, 0.50–0.88; p  0.006). In patients with
p27Kip1-positive tumors, OS was not different between pa-
tients treated with cisplatin-based chemotherapy and controls
(HR for death, 1.09; 95% CI, 0.82–1.45; p 0.54). The other
cell cycle regulators and Ki-67 did not predict benefit of
adjuvant cisplatin-based chemotherapy. None of these bi-
omarkers was significantly associated with OS of the patients
in the total study population. In conclusion, NSCLC patients
with p27Kip1-negative tumors benefit from adjuvant cispla-
tin-based chemotherapy after complete tumor resection. But
before establishing p27Kip1 as a routine marker for selection
of patients for adjuvant chemotherapy, the predictive value of
p27Kip1 has to be confirmed in patients from others trials.
In another study presented at 2008 ASCO Annual
Meeting, patterns of coexpression of ERCC1 and p27 were
analyzed by IHC in surgical resection specimens from 18
patients with NSCLC.129 Of 18 tumors, seven (39%) were
ERCC1 positive and three (17%) were p27Kip1 positive.
Coexpression of ERCC1 and p27Kip1 was as follows: one
case (6%) double positive, nine cases (50%) double negative,
six cases (33%) ERCC1 positive/p27Kip1 negative, and two
cases (11%) ERCC1 negative/p27Kip1 positive. P27Kip1
expression correlated with better differentiated adenocarci-
noma, but there was no correlation of ERCC1 or p27Kip1
with other clinic-pathologic parameters. The authors con-
cluded that the most common pattern of ERCC1 and p27Kip1
expression is double negativity, characteristic of 50% of
NSCLC, predicting the patient is more likely to benefit from
cisplatin-based adjuvant chemotherapy. Only 6% of patients
show coexpression of these markers, which would predict the
lowest likelihood of benefit.
DNA METHYLATION MARKERS
Epigenetic gene silencing is a molecular mechanism of
silencing a gene by methylating its promoter region. Epige-
netic silencing is involved in the initiation and progression of
several types of cancer, including lung cancer.130,131 The
detection of epigenetic alterations with the use of a method
like the methylation-specific PCR assay may allow for the
molecular staging of cancer.132 With this method, relatively
few genes are required to analyze each type of cancer.
The value of the methylation-specific PCR assay for
predicting the recurrence of early stage, resected NSCLC has
been examined in a recently published study.133 The authors
designed a nested case-control study of T1-2N0 NSCLC to test
the association between clinical outcome and the DNA methyl-
ation status of tumor, ipsilateral peribronchial and/or hilar lymph
nodes, and mediastinal lymph nodes. Seven genes thought to be
important in the biological development of lung cancer and
frequently methylated in this tumors were studied134–138: the
cyclin-dependent kinase inhibitor 2A gene p16, the H-cadherin
gene CDH13, the adenomatous polyposis coli gene APC, the
Ras association domain family one gene RASSF1A, the O6-
methylguanine-DNA methyl-transferase gene MGMT, the PYD
and CARD domain-containing gene ASC, and the death-asso-
ciated protein kinase one gene DAPK. The authors hypothesized
that the methylation-specific PCR assay could be used to define
patterns of DNA methylation that can delineate the behavior of
the primary tumor and to detect micrometastases in histologi-
cally negative lymph nodes.
Evidence of recurrent disease was evaluated in 715
patients with pathologically verified stage I cancer who un-
derwent lobectomy or greater resection at the Johns Hopkins
Hospital between January 1, 1986, and July 31, 2002. Fifty-
one patients who underwent curative resection but who had a
recurrence within 40 months after surgery (case patients)
were matched on the basis of age, NSCLC stage, sex, and
date of surgery (5 years) to 116 patients who did not have
a recurrence within 40 month after resection (controls). Nei-
ther case patients nor controls received adjuvant chemother-
apy. The authors also evaluated 162 paraffin-embedded tissue
blocks from 20 patients in a validation cohort (11 case
patients and nine matched controls).
Clinical and demographic variables were similar in case
patients and controls. The most frequent site of recurrence was
the ipsilateral lung (in 45.1% of patients), followed by metastasis
to bone (13.7%), brain (11.7%), and mediastinum (11.7%).
The covariates of pathologic stage, age, sex, histologic
characteristics of the tumor, smoking status, and race were
not associated with the risk of recurrence in patients with
histologically negative lymph nodes.
However, when compared with controls, the largest
differences in the univariate distribution among case patients
of the frequency of methylation in any type of tissue were
found in four genes—p16, CDH13, RASSF1A, and APC—
especially in tumors or mediastinal lymph nodes. When p16
or CDH13 was methylated in the primary tumor, the adjusted
odds ratio (OR) for recurrence was 3.50 (95% CI, 1.65–7.41;
p  0.001) and 2.12 (95% CI, 0.98–4.59; p  0.06),
respectively. When these same genes were methylated in
peribronchial and/or hilar lymph nodes, the OR was 3.62
(95% CI, 1.41—9.32; p  0.008) and 1.99 (95% CI, 0.81–
4.88; p  0.13), respectively. If methylation of p16 or
CDH13 was found in mediastinal lymph nodes, the OR for
recurrence was 4.67 (95% CI, 1.53–14.42; p  0.007) and
3.98 (95% CI, 1.22–13.01; p  0.02), respectively. Methyl-
ation of RASSF1A or APC in the tumor or mediastinal nodes
was not significantly associated with recurrence.
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The six possible pairs of these four genes were
examined for an association with recurrence. Among these
pairs, four had a significant association with recurrence in
at least one type of tissue: p16 and CDH13, CDH13 and
APC, APC and p16, and RASSF1A and p16. Methylation
of the gene pair p16 and CDH13 in the primary tumor
alone was associated with and OR for recurrence of 8.00
(95% CI, 2.50 –25.51; p  0.001) for the case patients
compared with the controls; when methylation of the two
genes was found in both the tumor and the mediastinal
lymph nodes, the estimated OR for recurrence was 15.50
(95% CI, 1.61–185.02; p  0.03) in the original cohort and
25.25(95% CI, 2.53–252.35; p  0.006) when the original
cohort was combined with the independent validation
cohort (Figure 7). Methylation of p16 and CDH13,
RASSF1A, or APC in paired tumor and mediastinal
lymph-node samples from the 51 case patients was asso-
ciated with early recurrence (median, 9 months; range,
5–30), whereas in the absence of methylation of these
markers, the median time to recurrence was 25 month after
surgery (range, 6 – 40; p  0.04).
In addition, Kaplan-Meier plots indicated that methyl-
ation of one or more of four genes—p16, CDH13, RASSF1A,
and APC—in any sample from the patient was related to the
duration of RFS. For example, the 5-year RFS rate in the
group of patients with two or more of the four methylated
genes in the primary tumor and mediastinal lymph nodes was
27.3% (95% CI, 6.5–53.9), when compared with 65.3% (95%
CI, 53.1–75.0) in the group with fewer than two methylated
genes at those sites (p  0.001). Methylation of both p16 and
CDH13 in tumor and mediastinal lymph nodes was associ-
ated with a 5-year RFS rate of 14.3% (95% CI, 0.7–46.5),
when compared with 63.1% (95% CI, 50.2–73.5) in the
absence of methylation of these genes (p  0.001).
In conclusion, this study indicates that the methylation
of the promoter regions of certain genes (p16, CDH13, APC,
and RASSF1A) in a resected NSCLC specimen is associated
with a significantly increased risk of early recurrences. These
genes are involved in cell-cycle control (p16), invasion and
metastasis (CDH13, APC), and RAS signaling (RASSF1A).
Other studies of p16 expression or promoter-region meth-
ylation in lung cancer have focused mostly on the primary
tumors,138 –143 but this one found that molecular examina-
tion of lymph nodes improves the assessment of risk of
recurrence. The methylation of these genes in histologi-
cally normal regional lymph nodes probably indicates the
presence of microscopically undetectable micrometastases.
Immunohistochemical analyses, for example, may miss a
rare cell in the background of normal tissue, whereas the
methylation-specific PCR assay is sufficiently sensitive to
detect a signal of DNA methylation. These results also
suggest that the detection of promoter methylation of
certain genes may identify cells with a potential for met-
astatic spread not only within NSCLC but also in lymph
nodes. The correlation between short survival and the
number of methylated genes in the regional and mediasti-
nal lymph nodes supports the presence of micrometastases
in those sites.
Recent promising results for predicting the risk of lung
cancer144 or its recurrence137 have been obtained by examin-
ing changes in gene methylation in sputum.144
As with other molecular markers, these results require
confirmation in a larger, prospectively studied cohort, before
the-four gene panel can be used to select patients for adjuvant
therapy in clinical practice.
Table 3 summarizes the role of the molecular markers
discussed in the review as prognostic factors for survival and
predictive markers of benefit from adjuvant chemotherapy.
FIGURE 7. Odds ratios for recur-
rence among case patients when
compared with controls, according
to methylated gene and site.
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As we previously mentioned, gene expression profiles
are useful in defining favorable and unfavorable prognostic
subsets and in selecting high-risk patients for adjuvant treat-
ment. These genomic strategies are consistently accurate in
estimating the risk of recurrence since they have been vali-
dated in independent cohorts of patients from multicenter
cooperative groups trials.
Among the molecular markers used as potential predic-
tors of a survival benefit from adjuvant chemotherapy,
ERCC1, RRM1, and BRCA1 are the most well-established
ones. For more than a decade, a number of clinical studies
have reported the association between levels of expression of
ERCC1 in several solid tumors and clinical outcome or
response to platinum-based chemotherapy. Data of BRCA1
are also fairly consistent, because several studies have exam-
ined its prognostic value and its potential role in predicting
differential chemotherapy sensitivity in NSCLC, showing
similar results.
Nevertheless, the prognostic significance of bTubIII
expression is less established and published reports in early
lung cancer are contrary to the data from advanced disease
about the value of bTubIII expression in predicting benefit
from antitubulin agents. So, further studies are needed to shed
light to these conflicting findings.
In relation with cell cycle regulators, p53, Ras, and p27
have also been extensively investigated as prognostic markers
in NSCLC, but results from individual studies have been
inconsistent, making it imperative that promising published
data be confirmed prospectively or retrospectively in large
phase III randomized trials.
Finally, the mechanism of aberrant gene silencing in
cancer by hypermethylation of DNA in promoter regions and
the clinical potential of this knowledge for risk assessment,
early diagnosis, prognostic monitoring, treatment, and the
prevention of cancer is a promising area of biological re-
search. Nowadays, published results are preliminary and
larger studies must be performed to determine the clinical
applicability of such findings.
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